Display options
Share it on

BMC Endocr Disord. 2013 Dec 01;13:56. doi: 10.1186/1472-6823-13-56.

Genetic analyses of bone morphogenetic protein 2, 4 and 7 in congenital combined pituitary hormone deficiency.

BMC endocrine disorders

Jana Breitfeld, Susanne Martens, Jürgen Klammt, Marina Schlicke, Roland Pfäffle, Kerstin Krause, Kerstin Weidle, Dorit Schleinitz, Michael Stumvoll, Dagmar Führer, Peter Kovacs, Anke Tönjes

Affiliations

  1. Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany. [email protected].

PMID: 24289245 PMCID: PMC4175098 DOI: 10.1186/1472-6823-13-56

Abstract

BACKGROUND: The complex process of development of the pituitary gland is regulated by a number of signalling molecules and transcription factors. Mutations in these factors have been identified in rare cases of congenital hypopituitarism but for most subjects with combined pituitary hormone deficiency (CPHD) genetic causes are unknown. Bone morphogenetic proteins (BMPs) affect induction and growth of the pituitary primordium and thus represent plausible candidates for mutational screening of patients with CPHD.

METHODS: We sequenced BMP2, 4 and 7 in 19 subjects with CPHD. For validation purposes, novel genetic variants were genotyped in 1046 healthy subjects. Additionally, potential functional relevance for most promising variants has been assessed by phylogenetic analyses and prediction of effects on protein structure.

RESULTS: Sequencing revealed two novel variants and confirmed 30 previously known polymorphisms and mutations in BMP2, 4 and 7. Although phylogenetic analyses indicated that these variants map within strongly conserved gene regions, there was no direct support for their impact on protein structure when applying predictive bioinformatics tools.

CONCLUSIONS: A mutation in the BMP4 coding region resulting in an amino acid exchange (p.Arg300Pro) appeared most interesting among the identified variants. Further functional analyses are required to ultimately map the relevance of these novel variants in CPHD.

References

  1. Development. 1996 Oct;122(10):2977-86 - PubMed
  2. Eur J Endocrinol. 2008 May;158(5):661-8 - PubMed
  3. Hum Mutat. 2013 Jan;34(1):57-65 - PubMed
  4. Exp Cell Res. 1997 Jan 10;230(1):28-37 - PubMed
  5. Genes Dev. 1996 Jul 1;10(13):1580-94 - PubMed
  6. Nat Methods. 2010 Aug;7(8):575-6 - PubMed
  7. Physiol Rev. 2007 Jul;87(3):933-63 - PubMed
  8. Genes Dev. 1994 Jan;8(2):133-46 - PubMed
  9. J Bone Miner Res. 2008 Apr;23(4):507-16 - PubMed
  10. Bioinformatics. 2009 Nov 1;25(21):2744-50 - PubMed
  11. Development. 1998 Mar;125(6):1005-15 - PubMed
  12. Horm Res. 2007;68 Suppl 5:138-44 - PubMed
  13. Science. 2002 Mar 22;295(5563):2231-5 - PubMed
  14. Clin Genet. 2000 May;57(5):337-46 - PubMed
  15. Dev Biol. 1999 Mar 1;207(1):176-88 - PubMed
  16. Rev Endocr Metab Disord. 2005 Aug;6(3):161-72 - PubMed
  17. Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 - PubMed
  18. Eur J Hum Genet. 2010 Jan;18(1):104-10 - PubMed
  19. Genes Dev. 1998 Jun 1;12(11):1691-704 - PubMed
  20. Growth Factors. 2004 Dec;22(4):233-41 - PubMed
  21. Cytokine Growth Factor Rev. 2005 Jun;16(3):265-78 - PubMed
  22. Dev Biol. 1997 Aug 15;188(2):235-47 - PubMed
  23. Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):43-60 - PubMed
  24. Exp Ther Med. 2011 Mar;2(2):337-341 - PubMed
  25. Mol Biol Evol. 2007 Aug;24(8):1586-91 - PubMed
  26. N Engl J Med. 1996 Aug 22;335(8):555-61 - PubMed
  27. Cancer Surv. 1996;27:41-64 - PubMed
  28. Curr Opin Genet Dev. 2005 Jun;15(3):332-40 - PubMed
  29. Calcif Tissue Int. 1998 Sep;63(3):221-9 - PubMed
  30. Nat Methods. 2010 Apr;7(4):248-9 - PubMed
  31. Hum Mutat. 2009 Aug;30(8):1237-44 - PubMed
  32. Genes Dev. 1995 Nov 15;9(22):2795-807 - PubMed
  33. Hum Mutat. 2010 Jul;31(7):781-7 - PubMed

Publication Types